Disc Medicine, Inc. financial data

Symbol
IRON on Nasdaq
Industry
Pharmaceutical Preparations
Location
321 Arsenal Street, Suite 101, Watertown, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Gemini Therapeutics, Inc. /DE (to 12/28/2022), FS Development Corp. (to 2/8/2021)
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.44K % +49.9%
Debt-to-equity 4.91 % -73.6%
Return On Equity -22.8 % +78.2%
Return On Assets -21.7 % +39.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 24.7M shares +29.9%
Common Stock, Shares, Outstanding 24.7M shares +26.2%
Entity Public Float 508M USD +1651%
Common Stock, Value, Issued 2K USD 0%
Weighted Average Number of Shares Outstanding, Basic 24.8M shares +30.9%
Weighted Average Number of Shares Outstanding, Diluted 24.8M shares +30.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 72.8M USD +58.9%
General and Administrative Expense 24.7M USD +46.5%
Operating Income (Loss) -97.5M USD -55.6%
Nonoperating Income (Expense) 16.9M USD +483%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -80.5M USD -34.8%
Income Tax Expense (Benefit) 81K USD -78.3%
Net Income (Loss) Attributable to Parent -80.6M USD -34.9%
Earnings Per Share, Basic -3.31 USD/shares +90.7%
Earnings Per Share, Diluted -3.31 USD/shares +90.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 343M USD +44.9%
Assets, Current 352M USD +45.4%
Property, Plant and Equipment, Net 211K USD +17.2%
Operating Lease, Right-of-Use Asset 1.79M USD +32.8%
Other Assets, Noncurrent 235K USD +103%
Assets 354M USD +45.3%
Accounts Payable, Current 5.27M USD -6.61%
Employee-related Liabilities, Current 2.16M USD +146%
Accrued Liabilities, Current 8.82M USD +119%
Liabilities, Current 14.9M USD +48.8%
Operating Lease, Liability, Noncurrent 1.26M USD +33.2%
Liabilities 16.1M USD +47.5%
Retained Earnings (Accumulated Deficit) -216M USD -59.7%
Stockholders' Equity Attributable to Parent 338M USD +45.2%
Liabilities and Equity 354M USD +45.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33.6M USD +5.26%
Net Cash Provided by (Used in) Financing Activities 15.9M USD -79.4%
Net Cash Provided by (Used in) Investing Activities -67K USD -131%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 24.7M shares +26.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -17.8M USD -142%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 343M USD +44.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 47K USD -21.7%
Deferred Tax Assets, Valuation Allowance 61.8M USD +71.1%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 62.3M USD +70.6%
Operating Lease, Liability 2.1M USD +57.5%
Depreciation 0 USD -100%
Payments to Acquire Property, Plant, and Equipment 67K USD +131%
Lessee, Operating Lease, Liability, to be Paid 2.42M USD +63.2%
Operating Lease, Liability, Current 767K USD +145%
Lessee, Operating Lease, Liability, to be Paid, Year Two 850K USD +123%
Lessee, Operating Lease, Liability, to be Paid, Year One 845K USD +127%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +90.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 323K USD +114%
Lessee, Operating Lease, Liability, to be Paid, Year Three 729K USD +85%
Deferred Tax Assets, Operating Loss Carryforwards 24.3M USD +28.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 336K USD
Operating Lease, Payments 186K USD -61.3%
Additional Paid in Capital 554M USD +50.5%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 26K USD +4%
Deferred Tax Assets, Net of Valuation Allowance 555K USD +32.1%
Share-based Payment Arrangement, Expense 8.56M USD +208%
Interest Expense 240K USD -96.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%